Suppr超能文献

性别对非梗阻性肥厚型心肌病中心力衰竭表现的影响。

Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy.

作者信息

Jang Ji-Hun, Shin Sung-Hee, Beak Yong Soo, Ko Kyu Yong, Kwon Sung Woo, Park Sang Don, Woo Seong Ill, Kim Dae Hyeok, Kwan Jun

机构信息

Division of Cardiology, Department of Internal Medicine, Inha University Hospital, 27, Inhang-ro, Jung-gu, Incheon, 400-711, Republic of Korea.

出版信息

Heart Vessels. 2020 Feb;35(2):214-222. doi: 10.1007/s00380-019-01492-0. Epub 2019 Sep 3.

Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease that represents a broad spectrum of morphologic features and clinical presentations. However, little is known about the impact of gender differences in heart failure (HF) development in non-obstructive HCM. We assessed clinical and echocardiographic parameters according to gender in patients with non-obstructive HCM and evaluated the impact of gender on HF presentation and cardiovascular (CV) outcomes in this population. We investigated 202 consecutive patients with non-obstructive HCM. Clinical parameters and conventional echocardiographic measurements including tissue Doppler measurements were evaluated and compared according to gender. Additionally, left ventricular (LV) deformation was assessed with global longitudinal strain (GLS) utilizing 2D speckle tracking software. Of the 202 patients (age = 63 ± 14 years, male: female = 141: 61), 51 patients (24.8%) presented with HF and female patients had HF more frequently (52.5% vs. 12.8%, P < 0.001). Females were older, had a higher prevalence of atrial fibrillation, had increased left atrial volume (LAV), and a higher ratio of early diastolic mitral inflow to early annular velocity (E/e') than males (70 ± 12 years vs. 59 ± 14 years, P < 0.001 for age; 51.4 ± 19.3 mL/m vs. 40.0 [Formula: see text] 13.4 mL/m, P < 0.001 for indexed LAV; 17.2 [Formula: see text] 6.0 vs. 13.0 [Formula: see text] 4.3, P < 0.001 for E/e'). While LV maximal thickness and LV ejection fraction were comparable between men and women, GLS was decreased significantly in female patients (- 13.5 [Formula: see text] 3.4% vs. - 15.6 [Formula: see text] 4.0%, P = 0.001 for GLS). Even after adjusting for clinical factors, female was independently associated with HF presentation (Odd ratio 5.19, 95% CI 2.24-12.03, P < 0.001). During a median follow-up duration 34.0 months, 20 patients (9.9%) had HF hospitalization or CV death. In a multivariable analysis, female gender was associated with higher risk of the composite of HF hospitalization or CV death and HF hospitalization alone than male (Adjusted hazard ratio [HR] = 3.31, 95% CI 1.17-9.35, P = 0.024 for primary composite outcome of HF hospitalization or CV death; adjusted HR = 4.78, 95% CI 1.53-14.96, P = 0.007 for HF hospitalization). In patients with non-obstructive HCM, female patients presented with HF more frequently and showed a higher risk of CV events than male patients. LA volume, E/e' and LV mechanics were different between the genders, suggesting that these might contribute to greater susceptibility to HF in women with HCM.

摘要

肥厚型心肌病(HCM)是一种遗传性心脏疾病,具有广泛的形态学特征和临床表现。然而,对于非梗阻性HCM患者心力衰竭(HF)发生过程中性别差异的影响知之甚少。我们根据性别评估了非梗阻性HCM患者的临床和超声心动图参数,并评估了性别对该人群HF表现和心血管(CV)结局的影响。我们调查了202例连续的非梗阻性HCM患者。根据性别对临床参数和包括组织多普勒测量在内的传统超声心动图测量进行评估和比较。此外,使用二维斑点追踪软件通过整体纵向应变(GLS)评估左心室(LV)变形。在这202例患者(年龄=63±14岁,男性:女性=141:61)中,51例患者(24.8%)出现HF,女性患者更频繁地出现HF(52.5%对12.8%,P<0.001)。女性年龄更大,心房颤动患病率更高,左心房容积(LAV)增加,舒张早期二尖瓣流入与早期瓣环速度之比(E/e')高于男性(年龄70±12岁对59±14岁,年龄P<0.001;LAV指数51.4±19.3mL/m对40.0[公式:见正文]13.4mL/m,LAV指数P<0.001;E/e'17.2[公式:见正文]6.0对13.0[公式:见正文]4.3,E/e'P<0.001)。虽然男性和女性之间的左心室最大厚度和左心室射血分数相当,但女性患者的GLS显著降低(-13.5[公式:见正文]3.4%对-15.6[公式:见正文]4.0%,GLS P=0.001)。即使在调整临床因素后,女性仍与HF表现独立相关(比值比5.19,95%可信区间2.24-12.03,P<0.001)。在中位随访期34.0个月期间,20例患者(9.9%)发生HF住院或CV死亡。在多变量分析中,女性与HF住院或CV死亡以及单独HF住院的复合风险高于男性(调整后危险比[HR]=3.31,95%可信区间1.17-9.35,HF住院或CV死亡的主要复合结局P=0.024;调整后HR=4.78,95%可信区间1.53-14.96,HF住院P=0.007)。在非梗阻性HCM患者中,女性患者比男性患者更频繁地出现HF,并且显示出更高的CV事件风险。性别之间的LAV、E/e'和左心室力学不同,表明这些可能导致HCM女性患者对HF的易感性更高。

相似文献

1
Impact of gender on heart failure presentation in non-obstructive hypertrophic cardiomyopathy.
Heart Vessels. 2020 Feb;35(2):214-222. doi: 10.1007/s00380-019-01492-0. Epub 2019 Sep 3.
2
Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy.
Heart. 2016 May 15;102(10):741-7. doi: 10.1136/heartjnl-2015-308576. Epub 2016 Feb 8.
4
Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
Am Heart J. 2020 Jan;219:58-69. doi: 10.1016/j.ahj.2019.10.004. Epub 2019 Oct 20.
6
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Circ Heart Fail. 2016 Apr;9(4):e002763. doi: 10.1161/CIRCHEARTFAILURE.115.002763.
7
Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy.
Arch Cardiovasc Dis. 2021 Feb;114(2):96-104. doi: 10.1016/j.acvd.2020.06.004. Epub 2020 Oct 7.
10
Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy.
Heart. 2016 Aug 1;102(15):1215-20. doi: 10.1136/heartjnl-2015-309121. Epub 2016 Mar 11.

引用本文的文献

2
A systematic review and meta-analysis of sex differences in clinical outcomes of hypertrophic cardiomyopathy.
Front Cardiovasc Med. 2023 Dec 5;10:1252266. doi: 10.3389/fcvm.2023.1252266. eCollection 2023.
3
Is There a Sex Difference in the Prognosis of Hypertrophic Cardiomyopathy? A Systematic Review and Meta-Analysis.
J Am Heart Assoc. 2023 Jun 6;12(11):e026270. doi: 10.1161/JAHA.122.026270. Epub 2023 May 26.
4
3-Dimensional Strain Analysis of Hypertrophic Cardiomyopathy: Insights From the NHLBI International HCM Registry.
JACC Cardiovasc Imaging. 2023 Apr;16(4):478-491. doi: 10.1016/j.jcmg.2022.10.005. Epub 2022 Dec 14.
5
Partially Represses the Abnormal Electrical Activity of SCN3B in Cardiac Arrhythmias by Downregulation of IL-2.
Front Cardiovasc Med. 2022 Jan 10;8:795675. doi: 10.3389/fcvm.2021.795675. eCollection 2021.
6
Gender-Related Differences in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.
Pulse (Basel). 2021 Aug 2;9(1-2):38-46. doi: 10.1159/000517618. eCollection 2021 Sep.
7
Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy.
BMC Cardiovasc Disord. 2020 Dec 9;20(1):516. doi: 10.1186/s12872-020-01807-4.
8
Sex, Survival, and Cardiomyopathy: Differences Between Men and Women With Hypertrophic Cardiomyopathy.
J Am Heart Assoc. 2019 Nov 5;8(21):e014448. doi: 10.1161/JAHA.119.014448. Epub 2019 Oct 30.

本文引用的文献

2
Women with hypertrophic cardiomyopathy have worse survival.
Eur Heart J. 2017 Dec 7;38(46):3434-3440. doi: 10.1093/eurheartj/ehx527.
5
Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored … Until Now.
Am J Med. 2017 Feb;130(2):119-123. doi: 10.1016/j.amjmed.2016.09.015. Epub 2016 Oct 14.
7
Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy.
J Am Coll Cardiol. 2016 Mar 29;67(12):1399-1409. doi: 10.1016/j.jacc.2016.01.023.
8
The Natural History of Nonobstructive Hypertrophic Cardiomyopathy.
Mayo Clin Proc. 2016 Mar;91(3):279-87. doi: 10.1016/j.mayocp.2016.01.002.
10
Hypertrophic cardiomyopathy: a review.
Clin Med Insights Cardiol. 2015 Jan 26;8(Suppl 1):53-65. doi: 10.4137/CMC.S15717. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验